Design, synthesis and evaluation of constrained methoxyethyl (cMOE) and constrained ethyl (cEt) nucleoside analogs - PubMed (original) (raw)
Design, synthesis and evaluation of constrained methoxyethyl (cMOE) and constrained ethyl (cEt) nucleoside analogs
Punit P Seth et al. Nucleic Acids Symp Ser (Oxf). 2008.
Abstract
Antisense drug discovery technology is a powerful method to modulate gene expression in animals and represents a novel therapeutic platform.(1) We have previously demonstrated that replacing 2'O-methoxyethyl (MOE, 2) residues in second generation antisense oligonucleotides (ASOs) with LNA (3) nucleosides improves the potency of some ASOs in animals. However, this was accompanied with a significant increase in the risk for hepatotoxicity.(2) We hypothesized that replacing LNA with novel nucleoside monomers that combine the structural elements of MOE and LNA might mitigate the toxicity of LNA while maintaining potency. To this end we designed and prepared novel nucleoside analogs 4 (S-constrained MOE, S-cMOE) and 5 (R-constrained MOE, R-cMOE) where the ethyl chain of the 2'O-MOE moiety is constrained back to the 4' position of the furanose ring. As part of the SAR series, we also prepared nucleoside analogs 7 (S-constrained ethyl, S-cEt) and 8 (R-constrained Ethyl, R-cEt) where the methoxymethyl group in the cMOE nucleosides was replaced with a methyl substituent. A highly efficient synthesis of the nucleoside phosphoramidites with minimal chromatography purifications was developed starting from cheap commercially available starting materials. Biophysical evaluation revealed that the cMOE and cEt modifications hybridize complementary nucleic acids with the same affinity as LNA while greatly increasing nuclease stability. Biological evaluation of oligonucleotides containing the cMOE and cEt modification in animals indicated that all of them possessed superior potency as compared to second generation MOE ASOs and a greatly improved toxicity profile as compared to LNA.
Similar articles
- Synthesis and biophysical evaluation of 2',4'-constrained 2'O-methoxyethyl and 2',4'-constrained 2'O-ethyl nucleic acid analogues.
Seth PP, Vasquez G, Allerson CA, Berdeja A, Gaus H, Kinberger GA, Prakash TP, Migawa MT, Bhat B, Swayze EE. Seth PP, et al. J Org Chem. 2010 Mar 5;75(5):1569-81. doi: 10.1021/jo902560f. J Org Chem. 2010. PMID: 20136157 - Structure and nuclease resistance of 2',4'-constrained 2'-O-methoxyethyl (cMOE) and 2'-O-ethyl (cEt) modified DNAs.
Pallan PS, Allerson CR, Berdeja A, Seth PP, Swayze EE, Prakash TP, Egli M. Pallan PS, et al. Chem Commun (Camb). 2012 Aug 25;48(66):8195-7. doi: 10.1039/c2cc32286b. Epub 2012 May 22. Chem Commun (Camb). 2012. PMID: 22614180 Free PMC article. - Short antisense oligonucleotides with novel 2'-4' conformationaly restricted nucleoside analogues show improved potency without increased toxicity in animals.
Seth PP, Siwkowski A, Allerson CR, Vasquez G, Lee S, Prakash TP, Wancewicz EV, Witchell D, Swayze EE. Seth PP, et al. J Med Chem. 2009 Jan 8;52(1):10-3. doi: 10.1021/jm801294h. J Med Chem. 2009. PMID: 19086780 - LNA-antisense rivals siRNA for gene silencing.
Jepsen JS, Wengel J. Jepsen JS, et al. Curr Opin Drug Discov Devel. 2004 Mar;7(2):188-94. Curr Opin Drug Discov Devel. 2004. PMID: 15603252 Review. - An overview of sugar-modified oligonucleotides for antisense therapeutics.
Prakash TP. Prakash TP. Chem Biodivers. 2011 Sep;8(9):1616-41. doi: 10.1002/cbdv.201100081. Chem Biodivers. 2011. PMID: 21922654 Review.
Cited by
- Splice-Modulating Antisense Oligonucleotides as Therapeutics for Inherited Metabolic Diseases.
Chen S, Heendeniya SN, Le BT, Rahimizadeh K, Rabiee N, Zahra QUA, Veedu RN. Chen S, et al. BioDrugs. 2024 Mar;38(2):177-203. doi: 10.1007/s40259-024-00644-7. Epub 2024 Jan 22. BioDrugs. 2024. PMID: 38252341 Free PMC article. Review. - Comparison of the efficacy of MOE and PMO modifications of systemic antisense oligonucleotides in a severe SMA mouse model.
Sheng L, Rigo F, Bennett CF, Krainer AR, Hua Y. Sheng L, et al. Nucleic Acids Res. 2020 Apr 6;48(6):2853-2865. doi: 10.1093/nar/gkaa126. Nucleic Acids Res. 2020. PMID: 32103257 Free PMC article. - Long Noncoding RNA in Cancer: Wiring Signaling Circuitry.
Lin C, Yang L. Lin C, et al. Trends Cell Biol. 2018 Apr;28(4):287-301. doi: 10.1016/j.tcb.2017.11.008. Epub 2017 Dec 20. Trends Cell Biol. 2018. PMID: 29274663 Free PMC article. Review. - Future directions for medicinal chemistry in the field of oligonucleotide therapeutics.
Hall J. Hall J. RNA. 2023 Apr;29(4):423-433. doi: 10.1261/rna.079511.122. Epub 2023 Jan 24. RNA. 2023. PMID: 36693762 Free PMC article. - Non-coding RNAs: the riddle of the transcriptome and their perspectives in cancer.
Diamantopoulos MA, Tsiakanikas P, Scorilas A. Diamantopoulos MA, et al. Ann Transl Med. 2018 Jun;6(12):241. doi: 10.21037/atm.2018.06.10. Ann Transl Med. 2018. PMID: 30069443 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Research Materials
Miscellaneous